News | July 06, 2012

Study reports 79 percent of diagnosis/treatment differed after review of brain SPECT images


July 6, 2012 — A new study titled “Specific Ways Brain SPECT Imaging Enhances Clinical Psychiatric Practice” was published June in the Journal of Psychoactive Drugs. It reveals how brain SPECT (single photon emission computed tomography) imaging can help clinicians more accurately diagnose and treat a wide variety of mental conditions by looking at the organ responsible for the decision-making, behaviors and overall cognitive functioning.

Co-authored by Daniel G. Amen, M.D., founder of Amen Clinics Inc; Kristen Willeumier, Ph.D. and Joseph Annibali, M.D., the study asked seven board-certified psychiatrists to evaluate 109 patients' files without the SPECT images and give their professional diagnosis and recommended treatment. After they saw the SPECT scans, 79 percent of the diagnosis and/or treatment would have been different. Additionally 22 percent of the patients showed unexpected brain injury and/or toxicity, while 60 percent showed new targets for medication or supplements.

"The SPECT images help the clinician understand where the brain is not functioning properly, so they can give a more accurate diagnosis and treatment offering," said Amen. He has conducted more than 73,000 SPECT scans on patients from 90 countries in the last 20 years.

"In our study, the use of SPECT neuroimaging modified the diagnostic thinking and led clinicians to make different, specific treatment recommendations in a high percentage of cases," wrote Amen, a board-certified child and adult psychiatrist.

Brain SPECT imaging is a form of neuroimaging that reveals the underlying physiology of emotional, behavioral and cognitive disorders such as anxiety, depression, ADD, memory loss, Alzheimer's, addiction, autism, seizures, strokes, toxic exposure and post-traumatic stress disorder.

For more information: www.amenclinics.com


Related Content

News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
News | Radiology Imaging

May 13, 2024 — National Basketball Association (NBA), the National Basketball Players Association (NBPA), and the Next ...

Time May 13, 2024
arrow
News | Radiopharmaceuticals and Tracers

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Radiation Therapy

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
Subscribe Now